Skip to main navigation Skip to search Skip to main content

Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders

  • Felicitas Rombold
  • , Eric Lauterbach
  • , Werner Felber
  • , Bruno Mueller-Oerlinghausen
  • , Bernd Ahrens
  • , Thomas Bronisch
  • , Birgit Kilb
  • , Ute Lewitzka
  • , Kneginja Richter
  • , Andreas Broocks
  • , Isabella Heuser
  • , Fritz Hohagen
  • , Arnim Quante*
  • *Corresponding author for this work
  • Charite - Universitatsmedizin Berlin
  • Universitätsklinikum Carl Gustav Carus
  • Max Planck Institute
  • Klinikum Nurnberg
  • Helios Kliniken Schwerin

Abstract

Objective. Patients with both major depression and personality disorders have a high risk of suicidal behavior. Lithium is meant to have anti-suicidal properties in patients with affective disorders. The anti-suicidal effect of lithium in patients with affective disorders and comorbid personality disorders has not been investigated yet.

Methods. A post-hoc analysis of a subsample of patients with depression and comorbid personality disorder (PD) and a recent suicide attempt (n = 19) from the prospective, placebo-controlled lithium intervention study (N = 167), was conducted.

Results. Three patients in the lithium group (n = 8) and two patients in the placebo group (n = 11) presented a suicide attempt throughout the course of the study. No differences related to suicidal behavior could be detected between the placebo group and the group with lithium intervention.

Conclusions. On the basis of the small sample size, among patients with comorbid PD, lithium does not seem to have an effect on suicidal behavior in contrast to patients with affective disorders without comorbid PD.

Original languageEnglish
JournalInternational Journal of Psychiatry in Clinical Practice
Volume18
Issue number4
Pages (from-to)300-303
Number of pages4
ISSN1365-1501
DOIs
Publication statusPublished - 01.10.2014

Funding

Dr. Mueller-Oerlinghausen is a member of the Drug Commission of the German Medical Association. Dr. Lewit-zka received grants from the BMBF (Bundesministerium fü r Bildung und Forschung) and Dalhousie University, Halifax, Canada, and grants from Lundbeck and Astra Zeneca. All other authors declare no conflict of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 10 - Reduced Inequalities
    SDG 10 Reduced Inequalities

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Dive into the research topics of 'Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders'. Together they form a unique fingerprint.

Cite this